Author

A. C. Aksu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

E. Y. Kala· 2 shared N. A. Lack· 2 shared T. Bagci-Onder· 2 shared T. Morova· 2 shared T. T. Onder· 2 shared A. Cingoz· 1 shared A. D. Cavga· 1 shared A. Kayabolen· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Y. Kala

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities

O. Yedier-Bayram, B. Gokbayrak, A. C. Aksu, A. D. Cavga, A. Kayabolen, E. Y. Kala, G. Karabiyik, R. Gunsay, T. Morova, F. Uyulur, N. A. Lack, T. T. Onder, T. Bagci-Onder

The paper introduces EPIKOL, a CRISPR-Cas9 library targeting epigenetic modifiers, and demonstrates its utility in identifying cancer-specific epigenetic vulnerabilities in breast and prostate cancer.

bioRxiv · May 14, 2021Cancer Biology